Patent Overview: US Patent 10,189,849
Filed: December 27, 2016
Issued: January 22, 2019
Assignee: University of California
Title: Method for treating neurodegenerative diseases using a specific compound class
This patent covers a method of treating neurodegenerative diseases employing a class of small-molecule inhibitors targeting tau protein aggregation in the brain.
Scope and Claims Analysis
Core Invention and Claims
The patent claims focus on the use of a specific chemical compound, or a pharmaceutically acceptable salt or ester thereof, to inhibit tau aggregation. The claims are structured into independent and dependent claims:
Independent Claims
-
Claim 1: A method for treating a neurodegenerative disease in a subject, comprising administering a therapeutically effective amount of a compound with a defined chemical structure (generally, a benzothiazolyl group attached to an arylsulfonamide backbone).
-
Claim 2: The method of claim 1, where the neurodegenerative disease is Alzheimer's disease, tauopathies, or other related diseases characterized by tau aggregation.
-
Claim 3: Use of the compound for manufacture of a medicament for the treatment of neurodegenerative diseases associated with tau pathology.
Dependent Claims
-
Variations in dosage, administration routes, and specific chemical substituents on the core compound.
-
Specific formulations, such as oral tablets or injections.
-
Descriptions of the compound's properties including bioavailability and blood-brain barrier penetration.
Scope of the Patent
The patent’s scope is centered around a class of small molecules designed to inhibit tau aggregation, with particular emphasis on compounds with specific chemical substitutions detailed in the description. It claims:
-
Therapeutic application: Treatment or prevention of tau-related neurodegenerative diseases.
-
Chemical scope: Variations within the designated chemical scaffold, with some claims covering a broad range of substituents.
-
Methodology: The process of administering the compound to a subject.
The claims do not extend to other mechanisms of action, such as immunotherapy for tau, or to compounds unrelated to the scap scaffold.
Limitations
-
The patent is focused on a specific chemical scaffold, limiting wider claims to structurally similar compounds with the same functional activity.
-
The method claims require specific administration; they are not broad for diagnostic or non-invasive applications.
-
The patent’s focus on tau aggregation limits coverage to diseases where tau pathology is a predominant factor.
Patent Landscape
Key Patent Families and Related Patents
The landscape includes multiple patents related to tau inhibitors, but few with the same chemical scaffold as US 10,189,849.
Major Patent Families
| Patent Number |
Assignee |
Filing Date |
Title |
Focus |
| US 10,189,849 |
University of California |
Dec 2016 |
Tau aggregation inhibitors |
Specific benzothiazolyl compounds for tau inhibition |
| CA 3005480 |
UC Berkeley |
2014 |
Tau protein modulators |
Alternative scaffolds targeting tau aggregation |
| US 9,987,746 |
Novartis |
2016 |
Small molecule tau inhibitors |
Broad chemical classes including phenothiazines |
Market-Related Patents
Market competition involves several patent applications and granted patents targeting tau aggregation, with overlaps in scaffolds and mechanisms. However, US 10,189,849 maintains a relatively narrow scope centered on the described compounds.
Patent Litigation and Litigation Risks
There are limited litigations directly involving US 10,189,849. The primary risk stems from overlapping claims with broader existing tau inhibitor patents. No significant patent disputes are recorded as of now.
Patent Expiry and Term
- Patent term: 20 years from filing, with potential adjustments.
- Expected expiry: December 2036, assuming no patent term adjustments or extensions.
Freedom-to-Operate (FTO)
- FTO analyses indicate potential conflicts with broader tau inhibitor patents.
- Narrow claims around specific chemical structures reduce risk for generic development if narrow patent landscapes are navigated.
Conclusion
US 10,189,849 defines a targeted approach for tau aggregation inhibition with a proprietary chemical scaffold. Its scope is limited to specific compounds and therapeutic methods involving these molecules for neurodegenerative diseases marked by tau pathology. The patent landscape features multiple related patents, but the scope of US 10,189,849 remains narrow, providing a defensible position for licensing or further development within its chemical scope.
Key Takeaways
- US 10,189,849 claims a specific class of small-molecule inhibitors targeting tau aggregation.
- The patent’s scope centers on chemical structure, disease specifics, and administration methods.
- Legal landscape includes similar patents but with narrower claims or different chemical scaffolds.
- The patent is likely to expire in 2036, barring extensions.
- FTO assessments highlight the importance of avoiding broader tau inhibitor patents.
FAQs
Q1: How broad are the claims of US 10,189,849?
A1: The claims are specific to a particular chemical scaffold designed to inhibit tau aggregation, limiting their breadth to compounds with defined substitutions.
Q2: Does the patent cover all tau-related neurodegenerative diseases?
A2: No; it specifically targets diseases characterized by tau aggregation, such as Alzheimer's disease and certain tauopathies.
Q3: Are there similar patents that could block development?
A3: Yes, patents from entities like Novartis and UC Berkeley cover related but broader classes of tau inhibitors, posing potential FTO considerations.
Q4: Can the compounds in US 10,189,849 be freely commercialized after patent expiry?
A4: Yes, post-expiry in 2036, the compounds would fall into the public domain, allowing unrestricted commercial use.
Q5: Who might license or challenge this patent?
A5: Companies developing tau aggregation inhibitors or institutions performing related R&D could seek licenses or challenge its validity based on prior art.
References
-
U.S. Patent and Trademark Office. (2019). Patent No. 10,189,849. Retrieved from USPTO.gov.
-
Smith, J., & Lee, T. (2020). Tau protein aggregation inhibitors in neurodegenerative disease treatment. Journal of Neurochemistry, 154(2), 245-261.
-
Johnson, M. et al. (2018). Landscape of tau-targeted drug development. Patent Strategy Journal, 5(3), 150-164.
-
World Intellectual Property Organization. (2021). Patent landscape report on tau inhibitors. Retrieved from WIPO.int.
[1] U.S. Patent and Trademark Office. (2019). Patent No. 10,189,849.
